Three-year results from a multicenter phase II study of capecitabine plus paclitaxel in metastatic breast cancer.

被引：0
|
作者：
Gradishar, WJ
Meza, L
Hill, T
Chen, YM
Varkey, JA
Hei, Y
Amin, B
机构：
[1] Northwestern Univ, Sch Med, Chicago, IL 60611 USA
[2] SW Oncol Associates, Lafayette, LA USA
[3] Roche Labs, Nutley, NJ USA
[4] Mid Dakota Clin, Bismarck, MD USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：S90 / S90
页数：1
相关论文
共 50 条
  • [31] A randomized, phase II trial of weekly paclitaxel versus weekly paclitaxel plus carboplatin for first-line metastatic breast cancer.
    Robert, N
    Loesch, D
    Lindquist, D
    Ratnam, S
    Hyman, W
    Whittaker, T
    Logie, K
    Kruger, S
    Pippen, J
    Liu, L
    Goldstein, L
    Asmar, L
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S129 - S129
  • [32] Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC)
    Northfelt, D. W.
    Allred, J. B.
    Liu, H.
    Hobday, T. J.
    Rodacker, M. W.
    Lyss, A. P.
    Fitch, T. R.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Phase I/II study of docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer.
    Tsai, JY
    Berkenblit, A
    Akerman, P
    Nadeem, A
    Rathore, R
    Harrington, D
    Roye, D
    Stuart, K
    Kennedy, TA
    Safran, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 322S - 322S
  • [34] A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
    Boland, Patrick McKay
    Fakih, Marwan
    Attwood, Kristopher
    Robins, Melissa
    Iyer, Renuka V.
    Ma, Wen Wee
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [35] A phase I/II study of nintedanib and capecitabine in refractory metastatic colorectal cancer.
    Boland, Patrick McKay
    Fakih, Marwan
    Lim, Dean
    Attwood, Kristopher
    Tan, Wei
    Mastri, Michalis
    Bies, Robert
    Fountzilas, Christos
    Iyer, Renuka V.
    Ma, Wen Wee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer.
    Fernando, N
    Yu, D
    Morse, M
    Blobe, G
    Odogwu, L
    Crews, J
    Polito, A
    Honeycutt, W
    Franklin, A
    Hurwitz, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 260S - 260S
  • [37] Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines: Preliminary results of a phase II study.
    Carbonero, IG
    Martin, M
    Casado, A
    Lluch, A
    Segura, PP
    de Paz, L
    Garcia-Conde, J
    Diaz-Rubio, E
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S4 - S4
  • [38] Phase 2 Trial of Paclitaxel Polyglumex with Capecitabine for Metastatic Breast Cancer
    Northfelt, Donald W.
    Allred, Jacob B.
    Liu, Heshan
    Hobday, Timothy J.
    Rodacker, Mark W.
    Lyss, Alan P.
    Fitch, Tom R.
    Perez, Edith A.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2014, 37 (02): : 167 - 171
  • [39] A phase II, open-label, multicenter, prospective study of paclitaxel plus capecitabine with subsequent capecitabine maintenance therapy as first-line treatment for metastatic or recurrent gastric cancer
    Shen, L.
    Gong, J.
    Zhang, X.
    Hu, B.
    Zhang, F.
    Zhang, J.
    Xu, N.
    Fan, Q.
    Bai, Y.
    Jiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [40] A Phase II study of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer.
    Zhao, Yannan
    Lv, Fangfang
    Chen, Shen
    Lu, Yunhua
    Cao, Enying
    Wang, Zhonghua
    Zhang, Jian
    Zhang, Sheng
    Cao, Jun
    Zheng, Chunlei
    Wang, Leiping
    Wang, Biyun
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345